Single-Cell Analysis Identifies Novel Cancer Biomarkers
Comprehensive scRNA-seq analysis reveals previously unknown cell populations and therapeutic targets
Client Overview
A leading academic medical center sought to understand the cellular heterogeneity within solid tumors to identify novel therapeutic targets and biomarkers for treatment response prediction.
The Challenge
Traditional bulk RNA-seq masks cellular heterogeneity by averaging gene expression across millions of cells. The research team needed to:
Resolve Cellular Heterogeneity
Identify and characterize rare cell populations within the tumor microenvironment that might play critical roles in disease progression and treatment resistance.
Handle Massive Data Scale
Process and analyze 500,000+ cells across 50 patient samples, requiring sophisticated computational infrastructure and analysis pipelines.
Integrate Multi-Modal Data
Combine scRNA-seq with clinical outcomes, histopathology, and genomic data to identify clinically relevant biomarkers.
Limited Bioinformatics Expertise
The research team had strong biological expertise but lacked the computational skills needed for advanced single-cell analysis.
The Solution: Comprehensive Single-Cell Analysis Pipeline
We developed an end-to-end analysis workflow using state-of-the-art single-cell analysis tools and custom algorithms for biomarker discovery.
1. Quality Control and Preprocessing
Rigorous QC to ensure high-quality data for downstream analysis:
- Cell Filtering: Removed low-quality cells (< 200 genes, > 20% mitochondrial content)
- Doublet Detection: Identified and removed cell doublets using Scrublet
- Ambient RNA Removal: Corrected for ambient RNA contamination using SoupX
- Normalization: Applied SCTransform for variance stabilization
2. Dimensionality Reduction and Clustering
Identified distinct cell populations using advanced clustering methods:
- PCA: Reduced dimensionality to top 50 principal components
- UMAP: Visualized cell populations in 2D space
- Graph-Based Clustering: Identified 25 distinct cell clusters using Leiden algorithm
- Marker Gene Identification: Found defining genes for each cluster using Wilcoxon rank-sum test
3. Cell Type Annotation
Comprehensive annotation combining automated and manual approaches:
- Reference-Based: Used SingleR with Human Primary Cell Atlas
- Marker-Based: Manual curation using canonical cell type markers
- Novel Populations: Characterized 3 previously unreported cell states
4. Differential Expression and Pathway Analysis
Identified genes and pathways associated with disease progression:
- Pseudobulk DE: Compared gene expression between responders and non-responders
- Cell-Type Specific Analysis: Identified markers unique to each population
- Gene Set Enrichment: Revealed activated pathways using GSEA
- Ligand-Receptor Analysis: Mapped cell-cell communication networks
Technologies Used:
Key Discoveries
Novel Cell Population
Identified a rare immunosuppressive myeloid population (2% of cells) highly enriched in non-responders. This population expressed unique markers including CD274, HAVCR2, and PDCD1LG2.
Predictive Biomarkers
Discovered 12 gene signatures that predict treatment response with 85% accuracy. These markers are now being validated in prospective clinical trials.
Therapeutic Targets
Identified 5 druggable targets enriched in treatment-resistant cells, including novel checkpoint molecules and metabolic enzymes.
Cell-Cell Interactions
Mapped extensive crosstalk between tumor cells and immune cells, revealing potential combination therapy strategies.
Analysis Outcomes
| Metric | Result |
|---|---|
| Total Cells Analyzed | 500,000+ |
| Cell Types Identified | 25 distinct populations |
| Novel Biomarkers | 12 predictive signatures |
| Publications | 3 peer-reviewed papers |
| Grant Funding Secured | $2.5M for follow-up studies |
Project Timeline
Data Generation (Month 1-3)
Sample collection, library preparation, and 10X Genomics sequencing of 50 patient samples.
Quality Control (Month 4)
Comprehensive QC, filtering, normalization, and batch correction across all samples.
Clustering & Annotation (Month 5-6)
Dimensionality reduction, clustering, and comprehensive cell type annotation.
Differential Analysis (Month 7-8)
Identified differentially expressed genes and pathways associated with treatment response.
Biomarker Discovery (Month 9-10)
Developed and validated predictive gene signatures, identified therapeutic targets.
Publication & Dissemination (Month 11-12)
Manuscript preparation, peer review, and presentation at major conferences.
SyncBio's expertise in single-cell analysis was transformative for our research. They not only processed the data but helped us interpret the biological significance of our findings. The novel cell population they identified has become the focus of our lab's research program and has attracted significant grant funding.
Technical Highlights
Batch Effect Correction
Samples were processed across multiple sequencing runs. We applied Harmony integration to remove technical batch effects while preserving biological variation.
Trajectory Analysis
Used Monocle3 to reconstruct developmental trajectories of immune cells, revealing differentiation pathways associated with treatment resistance.
Spatial Context
Integrated scRNA-seq data with spatial transcriptomics to map cell populations back to tissue architecture, revealing spatial organization patterns.
Interactive Visualization
Developed custom Shiny app allowing researchers to explore data interactively, query gene expression, and generate publication-quality figures.
Scientific Impact
- 3 Publications: High-impact papers in Nature Communications, Cancer Cell, and Clinical Cancer Research
- Grant Funding: $2.5M in NIH funding secured based on preliminary findings
- Clinical Translation: 2 biomarkers entering prospective clinical validation studies
- Collaboration: Established partnerships with 3 pharmaceutical companies for target validation
- Training: Trained 5 graduate students and postdocs in single-cell analysis methods
Unlock Insights from Your Single-Cell Data
Let SyncBio help you discover novel biomarkers and therapeutic targets through comprehensive single-cell analysis.
Start Your Project